본문 바로가기
KERD
논문KCI 등재

Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin

Hiroto Miwa|Katsuyuki Tozawa|Jiro Watari|Toshihiko Tomita|Tadayuki Oshima|Hirokazu Fukui
거트앤리버 소화기연관학회협의회|2020.05|Gut and Liver|제14권 제3호|pp. 281-290|DOI 10.5009/gnl19079

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

PathologyEradicationHelicobacter pyloriAspirinmolecularStomach neoplasms

초록

Whether Helicobacter pylori eradication actually reduces the risk of metachronous gastric cancer (MGC) development remains a controversial question. In this review, we addressed this topic by reviewing the results of clinical investigations and molecular pathological analyses of the roles of H. pylori eradication and aspirin administration in the prevention of MGC. In regard to the clinical studies, the results of meta-analyses and randomized control trials differ from those of retrospective studies: the former trials show that H. pylori eradication has a preventive effect on MGC, while the latter studies do not. This discrepancy may be at least partly attributable to differences in the follow-up periods: H. pylori eradication is more likely to prevent MGC over a long-term follow-up period (≥5 years) than over a short-term follow-up period. In addition, many studies have shown that aspirin may have an additive effect on MGC-risk reduction after H. pylori eradication has been achieved. Both H. pylori eradication and aspirin use induce molecular alterations in the atrophic gastritis mucosa but not in the intestinal metaplasia. Unfortunately, the molecular pathological analyses of these interventions have been limited by short follow-up periods. Therefore, a long-term prospective cohort is needed to clarify the changes in molecular events caused by these interventions.

Abstract

Whether Helicobacter pylori eradication actually reduces the risk of metachronous gastric cancer (MGC) development remains a controversial question. In this review, we addressed this topic by reviewing the results of clinical investigations and molecular pathological analyses of the roles of H. pylori eradication and aspirin administration in the prevention of MGC. In regard to the clinical studies, the results of meta-analyses and randomized control trials differ from those of retrospective studies: the former trials show that H. pylori eradication has a preventive effect on MGC, while the latter studies do not. This discrepancy may be at least partly attributable to differences in the follow-up periods: H. pylori eradication is more likely to prevent MGC over a long-term follow-up period (≥5 years) than over a short-term follow-up period. In addition, many studies have shown that aspirin may have an additive effect on MGC-risk reduction after H. pylori eradication has been achieved. Both H. pylori eradication and aspirin use induce molecular alterations in the atrophic gastritis mucosa but not in the intestinal metaplasia. Unfortunately, the molecular pathological analyses of these interventions have been limited by short follow-up periods. Therefore, a long-term prospective cohort is needed to clarify the changes in molecular events caused by these interventions.

참고문헌 (92)

  1. Correa P, "Helicobacter pylori and gastric carcinogenesis", Am J Surg Pathol, 19(Suppl 1), pp.S37~S43 (1995)
  2. Asaka M, "Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan", J Gastroenterol, 49, pp.1~8 (2014)
  3. "Helicobacter pylori eradication as a strategy for preventing gastric cancer: IARC working group reports, vol 8"[URL]
  4. Lee YC, "Association between Helicobacter pylori eradication and gastric cancer incidence : a systematic review and meta-analysis", Gastroenterology, 150, pp.1113~1124 (2016)
  5. Chen HN, "Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : evidence from a meta-analysis", Gastric Cancer, 19, pp.166~175 (2016)
  6. Yoon SB, "Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors : a meta-analysis", Helicobacter, 19, pp.243~248 (2014)
  7. Jung DH, "Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm : a meta-analysis", PLoS One, 10, pp.e0124725~ (2015)
  8. 방창석, "Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer", Journal of Korean Medical Science, 30(6), pp.749~756 (2015), 대한의학회
  9. Xiao S, "Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer : a systematic review and meta-analysis", J Gastroenterol, 54, pp.226~237 (2019)
  10. Sugano K, "Effect of Helicobacter pylori eradication on the incidence of gastric cancer : a systematic review and meta-analysis", Gastric Cancer, 22, pp.435~445 (2019)
  11. Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial", Lancet, 372, pp.392~397 (2008)
  12. Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
  13. Maehata Y, "Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer", Gastrointest Endosc, 75, pp.39~46 (2012)
  14. Kato M, "Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer : a multicentre retrospective cohort study by Osaka University ESD study group", Gut, 62, pp.1425~1432 (2013)
  15. Choi J, "Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma", Clin Gastroenterol Hepatol, 12, pp.793~800 (2014)
  16. Algra AM, "Effects of regular aspirin on long-term cancer incidence and metastasis : a systematic comparison of evidence from observational studies versus randomised trials", Lancet Oncol, 13, pp.518~527 (2012)
  17. Cao Y, "Population-wide impact of long-term use of aspirin and the risk for cancer", JAMA Oncol, 2, pp.762~769 (2016)
  18. 김영일, "Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study", Cancer Research and Treatment, 48(2), pp.798~805 (2016), 대한암학회
  19. Kong P, "The effects of anti-inflammatory drug treatment in gastric cancer prevention : an update of a meta-analysis", J Cancer, 7, pp.2247~2257 (2016)
  20. Huang XZ, "Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk : a dose-response meta-analysis", Oncotarget, 8, pp.4781~4795 (2017)
  21. Qiao Y, "Associations between aspirin use and the risk of cancers : a meta-analysis of observational studies", BMC Cancer, 18, pp.288~ (2018)
  22. Kim MH, "Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer", Am J Gastroenterol, 113, pp.845~854 (2018)
  23. Ulrich CM, "Non-steroidal anti-inflammatory drugs for cancer prevention : promise, perils and pharmacogenetics", Nat Rev Cancer, 6, pp.130~140 (2006)
  24. Sostres C, "Gastrointestinal effects of aspirin", Nat Rev Gastroenterol Hepatol, 8, pp.385~394 (2011)
  25. Chan AO, "Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer", Gut, 52, pp.502~506 (2003)
  26. Leung WK, "Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach", Clin Cancer Res, 12, pp.3216~3221 (2006)
  27. Chan AO, "Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation", Gut, 55, pp.463~468 (2006)
  28. Perri F, "Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication", Am J Gastroenterol, 102, pp.1361~1371 (2007)
  29. Sepulveda AR, "CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection", Gastroenterology, 138, pp.1836~1844 (2010)
  30. Nakajima T, "Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication", J Gastroenterol, 45, pp.37~44 (2010)
  31. Shin CM, "Changes in aberrant DNA methylation after Helicobacter pylori eradication : a long-term follow-up study", Int J Cancer, 133, pp.2034~2042 (2013)
  32. Kawanaka M, "Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment : analysis of molecular alterations by a randomized controlled trial", Br J Cancer, 114, pp.21~29 (2016)
  33. Asada K, "Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study", Gut, 64, pp.388~396 (2015)
  34. Maeda M, "High impact of methylation accumulation on metachronous gastric cancer : 5-year follow-up of a multicentre prospective cohort study", Gut, 66, pp.1721~1723 (2017)
  35. Liu X, "Gastric cancer in the era of precision medicine", Cell Mol Gastroenterol Hepatol, 3, pp.348~358 (2017)
  36. Huang KK, "Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer", Cancer Cell, 33, pp.137~150 (2018)
  37. Michigami Y, "Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer", Sci Rep, 7, pp.13384~ (2017)
  38. Michigami Y, "Long-term effects of H. pylorieradication on epigenetic alterations related to gastric carcinogenesis", Sci Rep, 8, pp.14369~ (2018)
  39. Ushijima T, "Molecular pathways : involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers", Clin Cancer Res, 18, pp.923~929 (2012)
  40. Kang GH, "Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis", Lab Invest, 83, pp.635~641 (2003)
  41. Maekita T, "High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk", Clin Cancer Res, 12(3 Pt 1), pp.989~995 (2006)
  42. Ando T, "DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients : its possible involvement in the formation of epigenetic field defect", Int J Cancer, 124, pp.2367~2374 (2009)
  43. Dong CX, "Promoter methylation of p16 associated with Helicobacter pylori infection in precancerous gastric lesions : a population-based study", Int J Cancer, 124, pp.434~439 (2009)
  44. Li WQ, "RUNX3 methylation and expression associated with advanced precancerous gastric lesions in a Chinese population", Carcinogenesis, 32, pp.406~410 (2011)
  45. Watari J, "Biomarkers predicting development of metachronous gastric cancer after endoscopic resection : an analysis of molecular pathology of Helicobacter pylori eradication", Int J Cancer, 130, pp.2349~2358 (2012)
  46. Maeda M, "Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication", Gastric Cancer, 21, pp.745~755 (2018)
  47. Steponaitiene R, "Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis", Mol Carcinog, 55, pp.376~386 (2016)
  48. Suzuki H, "Methylation-associated silencing of microRNA-34b", c in gastric cancer and its involvement in an epigenetic field defect, 2010, pp.31, 2066~2073
  49. Suzuki R, "Aberrant methylation of microRNA-34b", c is a predictive marker of metachronous gastric cancer risk, 2014, pp.49, 1135~1144
  50. Watari J, "K-ras mutations and cell kinetics in Helicobacter pylori associated gastric intestinal metaplasia : a comparison before and after eradication in patients with chronic gastritis and gastric cancer", J Clin Pathol, 60, pp.921~926 (2007)
  51. Sipponen P, "Gastric cancer risk in chronic atrophic gastritis : statistical calculations of cross-sectional data", Int J Cancer, 35, pp.173~177 (1985)
  52. de Vries AC, "The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection", Helicobacter, 12, pp.1~15 (2007)
  53. Kim N, "Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease", Helicobacter, 13, pp.245~255 (2008)
  54. Dinis-Ribeiro M, "Management of precancerous conditions and lesions in the stomach(MAPS) : guideline from the European Society of Gastrointestinal Endoscopy(ESGE), European Helicobacter Study Group(EHSG), European Society of Pathology(ESP), and the Sociedade Portuguesa de Endoscopia Digestiva(SPED)", Endoscopy, 44, pp.74~94 (2012)
  55. Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
  56. Rugge M, "Staging gastritis : an international proposal", Gastroenterology, 129, pp.1807~1808 (2005)
  57. Capelle LG, "The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis", Gastrointest Endosc, 71, pp.1150~1158 (2010)
  58. Yun CY, "Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors", Helicobacter, 23, pp.e12542~ (2018)
  59. Rugge M, "OLGA gastritis staging for the prediction of gastric cancer risk : a long-term follow-up study of 7436 patients", Am J Gastroenterol, 113, pp.1621~1628 (2018)
  60. Rugge M, "Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer : a 5-year prospective study of 1755 patients", Gut, 68, pp.11~17 (2019)
  61. Yue H, "The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer : a systematic review and meta-analysis", Gastric Cancer, 21, pp.579~587 (2018)
  62. Shichijo S, "Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication", Gastrointest Endosc, 84, pp.618~624 (2016)
  63. Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 3, pp.87~97 (1969)
  64. Hwang YJ, "Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication : a prospective study for up to 10 years", Aliment Pharmacol Ther, 47, pp.380~390 (2018)
  65. Leung WK, "Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals", Gastroenterology, 155, pp.67~75 (2018)
  66. Bae SE, "The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations", Helicobacter, 23, pp.e12464~ (2018)
  67. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
  68. Asaka M, "Strategy for eliminating gastric cancer in Japan", Helicobacter, 15, pp.486~490 (2010)
  69. Watari J, "Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development", World J Gastroenterol, 20, pp.5461~5473 (2014)
  70. Ito M, "Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy : a systematic review", J Gastroenterol, 44, pp.365~371 (2009)
  71. Choi JM, "Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention : a randomized controlled trial", Gastrointest Endosc, 88, pp.475~485 (2018)
  72. Mori G, "Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication : results of a large-scale, multicenter cohort study in Japan", Gastric Cancer, 19, pp.911~918 (2016)
  73. Bae SE, "Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm", Am J Gastroenterol, 109, pp.60~67 (2014)
  74. Cook NR, "Low-dose aspirin in the primary prevention of cancer : the Women’s Health Study : a randomized controlled trial", JAMA, 294, pp.47~55 (2005)
  75. Flossmann E, "Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies", Lancet, 369, pp.1603~1613 (2007)
  76. Rothwell PM, "Effect of daily aspirin on long-term risk of death due to cancer : analysis of individual patient data from randomised trials", Lancet, 377, pp.31~41 (2011)
  77. Tian W, "Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer", Eur J Cancer Prev, 19, pp.288~298 (2010)
  78. Bosetti C, "Aspirin and cancer risk : a quantitative review to 2011", Ann Oncol, 23, pp.1403~1415 (2012)
  79. Abnet CC, "Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas : results from a cohort study and a meta-analysis", Br J Cancer, 100, pp.551~557 (2009)
  80. Yang P, "Aspirin use and the risk of gastric cancer : a meta-analysis", Dig Dis Sci, 55, pp.1533~1539 (2010)
  81. Ye X, "Frequency-risk and duration-risk relationships between aspirin use and gastric cancer : a systematic review and meta-analysis", PLoS One, 8, pp.e71522~ (2013)
  82. Cheung KS, "Aspirin and risk of gastric cancer after Helicobacter pylori eradication : a territory-wide study", J Natl Cancer Inst, 110, pp.743~749 (2018)
  83. Wu CY, "Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients", J Clin Oncol, 28, pp.2952~2957 (2010)
  84. Zaridze D, "Aspirin protects against gastric cancer : results of a case-control study from Moscow, Russia", Int J Cancer, 82, pp.473~476 (1999)
  85. Akre K, "Aspirin and risk for gastric cancer : a population-based case-control study in Sweden", Br J Cancer, 84, pp.965~968 (2001)
  86. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
  87. Rugge M, "Gastric cancer as preventable disease", Clin Gastroenterol Hepatol, 15, pp.1833~1843 (2017)
  88. Kim N, "Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism", J Gastroenterol Hepatol, 34, pp.1287~1295 (2019)
  89. Chen HY, "High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer", Cancer Sci, 103, pp.73~79 (2012)
  90. Hughes LA, "The CpG island methylator phenotype: what’s in a name?", Cancer Res, 73, pp.5858~5868 (2013)
  91. Tahara T, "Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa", Dig Dis Sci, 55, pp.54~59 (2010)
  92. El-Serag HB, "Gene expression in Barrett’s esophagus : laser capture versus whole tissue", Scand J Gastroenterol, 44, pp.787~795 (2009)

관련 논문AI추천

Long-Term Effects of Helicobacter pylori Eradication on Metachronous Gastric Cancer Development오수연, Hyun Chae Jung, Jae Yong Park, Ji Min Choi, Joo Hyun Lim, Joo Sung Kim, Jung Kim, Sang Gyun Kim, Seung Jun Han거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제2호Characteristics of Primary and Metachronous Gastric Cancers Discovered after Helicobacter pylori Eradication: A Multicenter Propensity Score-Matched StudyEma Washio, Fumie Ikeda, Junji Umeno, Minako Hirahashi, Motohiro Esaki, Risa Hida, Shotaro Nakamura, Takanari Kitazono, Takayuki Matsumoto, Tomohiko Moriyama, Yuji Maehata거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제5호Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer최일주대한내과학회 · The Korean Journal of Internal Medicine2013 · 제28권 제5호Risk Assessment of Metachronous Gastric Neoplasm after Endoscopic Resection for Early Gastric Cancer According to Age at Helicobacter pylori Eradication정현수, Cho Soo-Jeong, Kim Bokyung, Kim Jiyoon, Kim Sang Gyun, Lee Jun Hee, Lee Seunghan, Na Yun Suk, Oh Mi Jin거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric CancerAmit Bhatt, Haruhisa Suzuki, Ichiro Oda, Masau Sekiguchi, Satoru Nonaka, Seiichiro Abe, Shigetaka Yoshinaga, Takeyoshi Minagawa, Yutaka Saito대한소화기내시경학회 · Clinical Endoscopy2018 · 제51권 제3호Clinical outcomes of metachronous recurrence of gastric epithelial neoplasia based on Helicobacter pylori infection status and microsatellite stabilityJaeyoung Kim, Woo Chul Chung, Yeon-Ji Kim대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호

이 간행물의 다른 논문 (15건)

To Do or Not to Do: Whether to Hold or Continue Antithrombotics before EndoscopyJoon Sung Kim, Byung-Wook Kimpp. 275-276Strategies to Increase the Participation Rate of Colorectal Cancer ScreeningYoon Suk Jungpp. 277-278A New Era of Endoscopic Ultrasound-Guided Tissue Acquisition for Next-Generation Sequencing for Pancreatic CancerTae Jun Songpp. 279-280The Role of Intestinal Fungi and Its Metabolites in Chronic Liver DiseasesJingxin Zhou, Junping Shi, Ningning You, Lili Zhuo, Yu Songpp. 291-296Management of Difficult Bile Duct Stones by Large Balloon, Cholangioscopy, Enteroscopy and EndosonographySuguru Mizuno, Minoru Tada, Tatsuya Sato, Yousuke Nakai, Ryunosuke Hakuta, Kazunaga Ishigaki, Kei Saito, Tomotaka Saito, Naminatsu Takahara, Kazuhiko Koike, Hiroyuki Isayama, Tsuyoshi Hamada, Hirofumi Kogurepp. 297-305
원문 보기